14-day Premium Trial Subscription Sign Up For FreeGet Free

Ascendis Pharma A/S Stock Forecast NASDAQ:ASND

Price Target and Analyst Ratings

Most Recent Rating

On August 26, 2021 "Wedbush" gave "$187.00" rating for ASND. The price target was set to $151.82+22.8%.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-08-26 $187.00 Reiterated by Wedbush $149.70 $151.82+22.8%
2021-08-26 $178.00 - $182.00 Target Raised by SVB Leerink $149.70 $123.67+1.6%
2021-08-26 $197.00 - $204.00 Target Raised by Morgan Stanley $149.70 $153.59+24.2%
2021-08-26 $178.00 - $185.00 Target Raised by Credit Suisse Group $149.70 $123.67+1.6%
2021-08-26 $172.00 - $175.00 Target Raised by JPMorgan Chase & Co. $149.70 $123.67+1.6%
2021-08-19 $0.40 - $0.35 Target Lowered by HC Wainwright $119.08 $118.82→0.6%
2021-07-21 $181.00 - $178.00 Target Lowered by SVB Leerink $122.00 $122.11+0.5%
2021-07-08 Hold Reiterated by Oppenheimer $124.72
2021-06-14 Positive - Outperform Target Lowered by SVB Leerink $134.40 $191.00 → $181.00
2021-06-14 Outperform Target Lowered by Wedbush $134.40 $219.00 → $189.00
2021-06-14 Overweight Target Lowered by Morgan Stanley $134.40 $201.00 → $197.00
2021-06-01 Buy Target Raised by Canaccord Genuity $133.53 $190.00 → $196.00
2021-05-28 Overweight Target Raised by Morgan Stanley $134.38 $199.00 → $201.00
2021-05-28 Outperform Target Raised by Credit Suisse Group $134.38 $176.00 → $178.00
2021-03-30 Outperform - Market Perform Downgraded by Oppenheimer $128.65
2021-03-18 Buy Target Raised by Canaccord Genuity $142.84 $172.00 → $190.00
2021-03-17 Outperform Target Lowered by Credit Suisse Group $144.00 $178.00 → $176.00
2021-03-12 Buy Target Raised by Canaccord Genuity $149.25 $172.00 → $190.00
2021-03-11 Outperform Target Lowered by Credit Suisse Group $150.00 $178.00 → $176.00
2021-03-11 Buy Initiated by Stifel Nicolaus $150.00
2020-12-17 Buy Initiated by Berenberg Bank $173.90 $216.00
2020-11-13 Overweight Target Raised by Morgan Stanley $165.68 $194.00 → $199.00
2020-11-12 Outperform Target Raised by SVB Leerink $166.64 $173.00 → $191.00
2020-11-12 Overweight Target Raised by Wells Fargo & Company $166.64 $176.00 → $190.00
2020-11-12 Outperform Target Raised by Credit Suisse Group $166.64 $158.00 → $178.00
2020-10-13 Overweight Target Raised by Morgan Stanley $160.00 $179.00 → $194.00
2020-09-30 Outperform Target Raised by Wedbush $154.32 $187.00 → $206.00
2020-09-14 Overweight Initiated by JPMorgan Chase & Co. $146.99
2020-08-31 Overweight Target Raised by Morgan Stanley $148.18 $177.00 → $179.00
2020-08-28 Outperform Target Raised by Credit Suisse Group $139.15 $154.00 → $158.00
2020-07-15 Overweight Target Lowered by Morgan Stanley $139.88 $181.00 → $177.00
2020-06-26 Buy Initiated by Wedbush $148.12 $188.00
2020-05-21 Overweight Target Raised by Morgan Stanley $146.84 $180.00 → $181.00
2020-05-20 Outperform Target Lowered by Oppenheimer $146.20 $219.00 → $208.00
2020-05-20 Outperform Target Raised by SVB Leerink $146.20 $170.00 → $173.00
2020-05-20 Outperform Target Raised by Credit Suisse Group $146.20 $149.00 → $154.00
2020-05-20 Outperform Target Raised by CSFB $146.20 $149.00 → $154.00
2020-04-20 Buy Target Raised by Stifel Nicolaus $138.59 $146.00 → $171.00
2020-04-20 Overweight Target Raised by Cantor Fitzgerald $138.59 $185.00 → $201.00
2020-04-20 Outperform Target Raised by Oppenheimer $138.59 $199.00 → $219.00
2020-04-20 Buy Target Raised by Canaccord Genuity $138.59 $166.00 → $170.00
2020-04-20 In-Line - Outperform Target Raised by Credit Suisse Group $138.59 $139.00 → $149.00
2020-04-20 Overweight Target Raised by JPMorgan Chase & Co. $138.59 $145.00 → $150.00
2020-04-20 Positive - Outperform Target Raised by SVB Leerink $138.59 $152.00 → $170.00

ASND Stock Trend

The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled.

Given the current short-term trend, the stock is expected to rise 33.53% during the next 3 months and, with a 90% probability hold a price between $185.50 and $253.41 at the end of this 3-month period.

Data

Date Bottom Mid Top
2021-09-30 $139.68 $165.11 $190.53
2021-10-01 $140.43 $165.86 $191.29
2021-10-04 $141.19 $166.62 $192.05
2021-10-05 $141.95 $167.37 $192.80
2021-10-06 $142.70 $168.13 $193.56
2021-10-07 $143.46 $168.89 $194.32
2021-10-08 $144.21 $169.64 $195.07
2021-10-11 $144.97 $170.40 $195.83
2021-10-12 $145.73 $171.16 $196.58
2021-10-13 $146.48 $171.91 $197.34
2021-10-14 $147.24 $172.67 $198.10
2021-10-15 $148.00 $173.43 $198.85
2021-10-18 $148.75 $174.18 $199.61
2021-10-19 $149.51 $174.94 $200.37
2021-10-20 $150.27 $175.69 $201.12
2021-10-21 $151.02 $176.45 $201.88
2021-10-22 $151.78 $177.21 $202.64
2021-10-25 $152.53 $177.96 $203.39
2021-10-26 $153.29 $178.72 $204.15
2021-10-27 $154.05 $179.48 $204.90
2021-10-28 $154.80 $180.23 $205.66
2021-10-29 $155.56 $180.99 $206.42
2021-11-01 $156.32 $181.75 $207.17
2021-11-02 $157.07 $182.50 $207.93
2021-11-03 $157.83 $183.26 $208.69
2021-11-04 $158.59 $184.01 $209.44
2021-11-05 $159.34 $184.77 $210.20
2021-11-08 $160.10 $185.53 $210.96
2021-11-09 $160.85 $186.28 $211.71
2021-11-10 $161.61 $187.04 $212.47

About Ascendis Pharma A/S

Ascendis Pharma A/S Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone that has completed Phase II clinical trials in children and adults to treat growth hormone deficiency (GHD) and other indications; and TransCon Treprostinil that has completed Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening d... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT